KR102649950B1 - 세포주로부터 랍도바이러스를 탐지 및 제거하는 방법 - Google Patents

세포주로부터 랍도바이러스를 탐지 및 제거하는 방법 Download PDF

Info

Publication number
KR102649950B1
KR102649950B1 KR1020217038994A KR20217038994A KR102649950B1 KR 102649950 B1 KR102649950 B1 KR 102649950B1 KR 1020217038994 A KR1020217038994 A KR 1020217038994A KR 20217038994 A KR20217038994 A KR 20217038994A KR 102649950 B1 KR102649950 B1 KR 102649950B1
Authority
KR
South Korea
Prior art keywords
rna
rhabdovirus
delete delete
virus
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217038994A
Other languages
English (en)
Korean (ko)
Other versions
KR20210154988A (ko
Inventor
조엘 헤인즈
Original Assignee
다케다 백신즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 다케다 백신즈 인코포레이티드 filed Critical 다케다 백신즈 인코포레이티드
Publication of KR20210154988A publication Critical patent/KR20210154988A/ko
Application granted granted Critical
Publication of KR102649950B1 publication Critical patent/KR102649950B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/205—Rhabdoviridae, e.g. rabies virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/20011—Rhabdoviridae
    • C12N2760/20051—Methods of production or purification of viral material
    • C12N2760/20052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217038994A 2013-10-03 2014-10-03 세포주로부터 랍도바이러스를 탐지 및 제거하는 방법 Active KR102649950B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361886438P 2013-10-03 2013-10-03
US61/886,438 2013-10-03
KR1020167010089A KR102474663B1 (ko) 2013-10-03 2014-10-03 세포주로부터 랍도바이러스를 탐지 및 제거하는 방법
PCT/US2014/059060 WO2015051255A1 (en) 2013-10-03 2014-10-03 Methods of detection and removal of rhabdoviruses from cell lines

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167010089A Division KR102474663B1 (ko) 2013-10-03 2014-10-03 세포주로부터 랍도바이러스를 탐지 및 제거하는 방법

Publications (2)

Publication Number Publication Date
KR20210154988A KR20210154988A (ko) 2021-12-21
KR102649950B1 true KR102649950B1 (ko) 2024-03-22

Family

ID=52779185

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020217038994A Active KR102649950B1 (ko) 2013-10-03 2014-10-03 세포주로부터 랍도바이러스를 탐지 및 제거하는 방법
KR1020167010089A Active KR102474663B1 (ko) 2013-10-03 2014-10-03 세포주로부터 랍도바이러스를 탐지 및 제거하는 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020167010089A Active KR102474663B1 (ko) 2013-10-03 2014-10-03 세포주로부터 랍도바이러스를 탐지 및 제거하는 방법

Country Status (9)

Country Link
US (5) US10501500B2 (enExample)
EP (1) EP3052631B1 (enExample)
JP (6) JP2016533172A (enExample)
KR (2) KR102649950B1 (enExample)
CN (1) CN106103720A (enExample)
AU (3) AU2014329403B2 (enExample)
CA (1) CA2926225A1 (enExample)
SG (3) SG10202107054TA (enExample)
WO (1) WO2015051255A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140200831A1 (en) * 2011-01-28 2014-07-17 Schlumberger Technology Corporation Pipe Damage Interpretation System
SG10202107054TA (en) 2013-10-03 2021-08-30 Takeda Vaccines Inc Methods of detection and removal of rhabdoviruses from cell lines
JP6893174B2 (ja) 2015-01-16 2021-06-23 タケダ ワクチン，インコーポレイテッド 粒子に含まれる逆転写酵素活性の検出
CA2977405A1 (en) 2015-03-05 2016-09-09 Boehringer Ingelheim Vetmedica, Inc. Marker system, in particular for baculovirus-expressed subunit antigens
CN104962580B (zh) * 2015-06-30 2018-04-27 浙江大学 一种重组植物弹状病毒载体及其构建方法
ES2922081T3 (es) * 2015-11-01 2022-09-07 Glycobac Llc Líneas celulares libres de virus y métodos para su obtención
CN109182277B (zh) * 2018-09-07 2021-05-07 中国水产科学研究院长江水产研究所 一种黄鳝弹状病毒CrERV及RT-PCR检测引物及应用
EP4600699A3 (en) 2018-12-02 2025-10-22 Gentex Corporation Systems, devices and methods for microvibration data extraction using a time of flight (tof) imaging device
US11858962B2 (en) 2020-02-06 2024-01-02 Boehringer Ingelheim Vetmedica Gmbh Polypeptides useful for detecting anti-rhabdovirus antibodies
WO2021163079A1 (en) * 2020-02-10 2021-08-19 Biomarin Pharmaceutical Inc. Virus-free cell cultures
CN114686599A (zh) * 2020-12-30 2022-07-01 北京五加和基因科技有限公司 宿主昆虫细胞dna残留含量定量检测方法及试剂盒
US20240238401A1 (en) 2021-05-21 2024-07-18 Takeda Vaccines, Inc. Solid composition, freeze-drying method and glass vial
CN115491377B (zh) * 2021-06-18 2025-09-16 北京三诺佳邑生物技术有限责任公司 一种诱导rna干扰和降低并清除细胞中病毒污染的核苷酸序列及应用
CN116731953A (zh) * 2022-03-01 2023-09-12 成都威斯克生物医药有限公司 弹状病毒阴性草地贪夜蛾昆虫细胞株及其筛选、鉴定和应用
CN118547114A (zh) * 2024-05-29 2024-08-27 长春生物制品研究所有限责任公司 一种用于Sf弹状病毒荧光定量检测的引物、探针、试剂盒及方法
CN120700212A (zh) * 2025-08-27 2025-09-26 北京昭衍生物技术有限公司 一种用于检测弹状病毒的qPCR引物探针组合物、试剂盒及其应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5024947A (en) * 1987-07-24 1991-06-18 Cetus Corporation Serum free media for the growth on insect cells and expression of products thereby
US5457189A (en) * 1989-12-04 1995-10-10 Isis Pharmaceuticals Antisense oligonucleotide inhibition of papillomavirus
US5646262A (en) * 1994-07-28 1997-07-08 Georgetown University Antisense oligonucleotides against hepatitis B viral replication
US6103526A (en) 1998-10-08 2000-08-15 Protein Sciences Corporation Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using
EP2261230B1 (en) * 2002-09-11 2017-05-10 Chugai Seiyaku Kabushiki Kaisha Protein purification method
JP2005168485A (ja) * 2003-11-20 2005-06-30 Tsutomu Suzuki ｓｉＲＮＡの設計方法
HUE032422T2 (en) 2006-09-29 2017-09-28 Takeda Vaccines Inc Norovirus vaccine preparations
CA2683977C (en) 2007-03-14 2017-04-25 Ligocyte Pharmaceuticals, Inc. A method of norovirus virus-like particle purification comprising ion exchange chromatography
US20110111496A1 (en) * 2007-06-29 2011-05-12 Chiang Li BACTERIA-MEDIATED GENE MODULATION VIA microRNA MACHINERY
SG10201601660YA (en) 2007-09-18 2016-04-28 Takeda Vaccines Inc Method of conferring a protective immune response to norovirus
AU2009279456B2 (en) 2008-08-08 2015-02-05 Takeda Vaccines, Inc. Virus-like particles comprising composite capsid amino acid sequences for enhanced cross reactivity
KR20110071011A (ko) * 2008-10-20 2011-06-27 아보트 러보러터리즈 Ｉｌ-18에 결합하는 항체 및 이의 정제 방법
EP2412817B2 (en) * 2009-03-27 2019-06-05 Asahi Kasei Medical Co., Ltd. Method for removing viruses in high-concentration monoclonal antibody solution
WO2012083363A1 (en) * 2010-12-22 2012-06-28 Murdoch Childrens Research Institute A method of treatment
EA029470B1 (ru) 2011-07-11 2018-03-30 Такеда Вэксинс, Инк. Способ стимулирования формирования защитного иммунитета против норовируса
CN102605106B (zh) * 2012-03-29 2013-09-04 浙江省检验检疫科学技术研究院 蚕微孢子虫、核型多角体病毒和浓核病毒的三重荧光pcr检测方法及试剂盒和引物、探针
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
SG10202107054TA (en) 2013-10-03 2021-08-30 Takeda Vaccines Inc Methods of detection and removal of rhabdoviruses from cell lines
ES2922081T3 (es) 2015-11-01 2022-09-07 Glycobac Llc Líneas celulares libres de virus y métodos para su obtención
CN114807009A (zh) 2022-03-28 2022-07-29 成都纳微金生物技术有限公司 一种不依赖血清的无弹状病毒污染的sf9细胞株、筛选方法及应用

Also Published As

Publication number Publication date
US12018052B2 (en) 2024-06-25
KR20210154988A (ko) 2021-12-21
SG11201602585XA (en) 2016-05-30
EP3052631A4 (en) 2017-06-14
KR20160062049A (ko) 2016-06-01
US12479891B2 (en) 2025-11-25
SG10201802772YA (en) 2018-05-30
US20220213150A1 (en) 2022-07-07
AU2020294216A1 (en) 2021-01-28
AU2014329403A1 (en) 2016-05-05
WO2015051255A1 (en) 2015-04-09
KR102474663B1 (ko) 2022-12-07
CA2926225A1 (en) 2015-04-09
JP2023126495A (ja) 2023-09-07
JP2024050747A (ja) 2024-04-10
US11286282B2 (en) 2022-03-29
EP3052631B1 (en) 2019-08-07
US10501500B2 (en) 2019-12-10
AU2020294216B2 (en) 2022-11-24
CN106103720A (zh) 2016-11-09
JP2022009010A (ja) 2022-01-14
US20200190146A1 (en) 2020-06-18
US20250109172A1 (en) 2025-04-03
AU2022259826B2 (en) 2025-01-02
JP7191175B2 (ja) 2022-12-16
SG10202107054TA (en) 2021-08-30
US20160244487A1 (en) 2016-08-25
JP2023024506A (ja) 2023-02-16
EP3052631A1 (en) 2016-08-10
US20230303633A1 (en) 2023-09-28
AU2014329403B2 (en) 2020-10-08
JP2020036613A (ja) 2020-03-12
JP2016533172A (ja) 2016-10-27
US12006341B2 (en) 2024-06-11
AU2022259826A1 (en) 2023-01-19

Similar Documents

Publication Publication Date Title
KR102649950B1 (ko) 세포주로부터 랍도바이러스를 탐지 및 제거하는 방법
US20220378904A1 (en) Hmpv mrna vaccine composition
WO2022245888A1 (en) Seasonal flu rna vaccines and methods of use
WO2021222304A1 (en) Sars-cov-2 rna vaccines
Luo et al. Amino acid mutation in position 349 of glycoprotein affect the pathogenicity of rabies virus
JP2018527948A (ja) ウイルス由来の治療剤を解析する方法
Makovitzki et al. Evaluation of a downstream process for the recovery and concentration of a Cell-Culture-Derived rVSV-Spike COVID-19 vaccine candidate
EP3121268B1 (en) Methods for purification of a virus produced in vitro and clearance assay for the virus
KR20230041686A (ko) 아넬로바이러스를 확인 및 특징화하는 방법 및 이의 용도
US20230272351A1 (en) Covid assay controls
HK1227433A1 (en) Methods of detection and removal of rhabdoviruses from cell lines
HK1227433B (en) Methods of detection and removal of rhabdoviruses from cell lines
JP6893174B2 (ja) 粒子に含まれる逆転写酵素活性の検出
CN118766948A (zh) 氯法拉滨在制备预防或治疗痘病毒感染药物中的应用
CN120700002A (zh) 携带polyUC的重组寨卡病毒及其应用
Tizard et al. Detection and Characterization of a Distinct
HK1231118B (en) Methods for purification of a virus produced in vitro and clearance assay for the virus

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601